Home > Publications Database > Supplementing Single‐Arm Trials with External Control Arms—Evaluation of German Real‐World Data > print

001     282544
005     20251201103322.0
024 7 _ |a 10.1002/cpt.3684
|2 doi
024 7 _ |a 0009-9236
|2 ISSN
024 7 _ |a 1085-8733
|2 ISSN
024 7 _ |a 1532-6535
|2 ISSN
037 _ _ |a DZNE-2025-01307
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Russek, Martin
|0 P:(DE-2719)9002837
|b 0
|u dzne
245 _ _ |a Supplementing Single‐Arm Trials with External Control Arms—Evaluation of German Real‐World Data
260 _ _ |a Hoboken, NJ
|c 2025
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1764581485_18435
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a As single-arm trials (SATs) are increasingly used in pharmaceutical research, the validity of such study designs needs to be critically assessed. We characterize the feasibility of supplementing SATs with real-world data (RWD)-derived external control arms by determining the proportion of SATs on breast cancer and amyotrophic lateral sclerosis (ALS) for which an external control arm based on RWD can be constructed. The main outcome measure is the number and percentage of trials for which all important eligibility criteria and at least one primary endpoint could be identified in one of five German RWD sources. We surveyed all SATs concerning breast cancer or ALS treatment registered in the European Union’s clinical trial registers between 2004 and 2023. Ten out of 379 breast cancer SATs and 2 of 11 ALS SATs could feasibly be supplemented with RWD-derived external control arms, if all important eligibility criteria and a primary endpoint have to be identifiable in the RWD source. Ninety-three breast cancer trials had at least one outcome ascertainable in a RWD source, and 35 trials had all important eligibility criteria recorded in a RWD source. Nine ALS trials had at least one primary endpoint ascertainable in RWD sources, and 2 had all important eligibility criteria recorded in a RWD source. Our study shows that SATs with RWD-derived external control arms will rarely be suitable to establish treatment effects of medicines in the current setting for the investigated phenotypes and that SATs should be designed with limitations of the source of external controls in mind.
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
700 1 _ |a Peltner, Jonas
|0 P:(DE-2719)9002192
|b 1
700 1 _ |a Haenisch, Britta
|0 P:(DE-2719)2810511
|b 2
|e Last author
773 _ _ |a 10.1002/cpt.3684
|g Vol. 118, no. 6, p. 1443 - 1450
|0 PERI:(DE-600)2040184-X
|n 6
|p 1443 - 1450
|t Clinical pharmacology & therapeutics
|v 118
|y 2025
|x 0009-9236
856 4 _ |u https://pub.dzne.de/record/282544/files/DZNE-2025-01307%20SUP1.docx
856 4 _ |u https://pub.dzne.de/record/282544/files/DZNE-2025-01307%20SUP2.xlsx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/282544/files/DZNE-2025-01307.pdf
856 4 _ |u https://pub.dzne.de/record/282544/files/DZNE-2025-01307%20SUP1.doc
856 4 _ |u https://pub.dzne.de/record/282544/files/DZNE-2025-01307%20SUP1.odt
856 4 _ |u https://pub.dzne.de/record/282544/files/DZNE-2025-01307%20SUP1.pdf
856 4 _ |u https://pub.dzne.de/record/282544/files/DZNE-2025-01307%20SUP2.csv
856 4 _ |u https://pub.dzne.de/record/282544/files/DZNE-2025-01307%20SUP2.ods
856 4 _ |u https://pub.dzne.de/record/282544/files/DZNE-2025-01307%20SUP2.xls
856 4 _ |u https://pub.dzne.de/record/282544/files/DZNE-2025-01307.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9002837
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9002192
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2810511
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 0
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-27
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CLIN PHARMACOL THER : 2022
|d 2024-12-27
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-27
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-27
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CLIN PHARMACOL THER : 2022
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-27
920 1 _ |0 I:(DE-2719)1013010
|k AG Hänisch
|l Pharmacoepidemiology
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1013010
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21